CAR T-cell therapy entails extracting a patient’s own T-cells and genetically re-engineering them ex vivo to express an antigen on cancer cells (ie, the manufacturing process). Then, the CAR T-cell product is reinfused back into the patient, where it hopefully undergoes expansion.
“The main rationale from the cytotoxic era is to increase efficacy by combining agents that have different mechanisms and nonoverlapping toxicities. The question is whether we can replace nonspecific cytotoxic agents with a specific, more effective immunotherapeutic,” said Donna Przepiorka, MD, PhD, at ASH 2017.
As the number of patients receiving immune checkpoint blockade grows, the combination of radiation and immunotherapy has become increasingly relevant, particularly in the palliative care setting, where radiation therapy is used to treat painful lesions or brain metastases.
Results 1 - 10 of 27